ALX ONCOLOGY HOLDINGS INC Earnings Per Share (Basic)
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Earnings Per Share (Basic) of -$0.13 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC earnings per share, basic for the quarter ending 2026-06-30 was -$0.13.
- ALX ONCOLOGY HOLDINGS INC earnings per share, basic for the quarter ending 2026-03-31 was -$0.17.
- ALX ONCOLOGY HOLDINGS INC earnings per share, basic for the quarter ending 2025-09-30 was -$0.41.
- ALX ONCOLOGY HOLDINGS INC earnings per share, basic for the quarter ending 2025-06-30 was -$0.49.
- ALX ONCOLOGY HOLDINGS INC earnings per share, basic for fiscal 2025 was -$1.90.
- ALX ONCOLOGY HOLDINGS INC earnings per share, basic for fiscal 2024 was -$2.58.
- ALX ONCOLOGY HOLDINGS INC earnings per share, basic for fiscal 2023 was -$3.74.
- ALX ONCOLOGY HOLDINGS INC earnings per share, basic for fiscal 2022 was -$3.03.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.13 10-Q · filed 2026-08-06 | -$0.30 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | -$0.17 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | -$1.90 10-K · filed 2026-03-09 | |||
| 2025-09-30 | -$0.41 10-Q · filed 2025-11-07 | -$1.48 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | -$0.49 10-Q · filed 2026-08-06 | -$1.05 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | -$0.58 10-Q · filed 2026-05-08 | |||
| 2024-12-31 | -$2.58 10-K · filed 2026-03-09 | |||
| 2024-09-30 | -$0.58 10-Q · filed 2025-11-07 | -$2.05 10-Q · filed 2025-11-07 | ||
| 2024-06-30 | -$0.76 10-Q · filed 2025-08-12 | -$1.47 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$0.71 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$3.74 10-K · filed 2026-03-09 | |||
| 2023-09-30 | -$1.24 10-Q · filed 2024-11-07 | -$2.82 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | -$0.84 10-Q · filed 2024-08-12 | -$1.57 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$0.74 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$3.03 10-K · filed 2025-03-06 | |||
| 2022-09-30 | -$0.87 10-Q · filed 2023-11-13 | -$2.28 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | -$0.81 10-Q · filed 2023-08-10 | -$1.41 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$0.60 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$0.70 derived: net income ÷ weighted average shares · filed 2024-03-07 | -$1.31 derived: net income ÷ weighted average shares · filed 2024-03-07 | -$1.72 derived: net income ÷ weighted average shares · filed 2024-03-07 | -$2.07 10-K · filed 2024-03-07 |
| 2021-09-30 | -$0.61 10-Q · filed 2022-11-08 | -$1.01 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$1.37 10-Q · filed 2022-11-08 | -$1.86 derived: net income ÷ weighted average shares · filed 2023-03-09 |
| 2021-06-30 | -$0.40 10-Q · filed 2022-08-08 | -$0.76 10-Q · filed 2022-08-08 | -$1.25 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$1.62 derived: net income ÷ weighted average shares · filed 2023-03-09 |
| 2021-03-31 | -$0.35 derived: net income ÷ weighted average shares · filed 2021-05-17 | -$0.85 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$1.22 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$2.09 derived: net income ÷ weighted average shares · filed 2023-03-09 |
| 2020-12-31 | -$0.50 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$0.88 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$1.85 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$2.76 10-K · filed 2023-03-09 |
| 2020-09-30 | -$0.36 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$1.51 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$2.67 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$4.20 derived: net income ÷ weighted average shares · filed 2022-02-28 |
| 2020-06-30 | -$4.41 derived: net income ÷ weighted average shares · filed 2021-08-12 | -$6.78 derived: net income ÷ weighted average shares · filed 2021-08-12 | -$9.62 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$10.97 derived: net income ÷ weighted average shares · filed 2022-02-28 |
| 2020-03-31 | -$2.37 derived: net income ÷ weighted average shares · filed 2021-05-17 | -$5.19 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$6.53 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$8.21 derived: net income ÷ weighted average shares · filed 2022-02-28 |
| 2019-12-31 | -$2.83 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$4.16 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$5.84 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$7.56 derived: net income ÷ weighted average shares · filed 2022-02-28 |
| 2019-09-30 | -$1.33 derived: net income ÷ weighted average shares · filed 2021-03-18 | -$3.00 derived: net income ÷ weighted average shares · filed 2021-03-18 | -$4.72 derived: net income ÷ weighted average shares · filed 2020-11-12 | |
| 2019-06-30 | -$1.68 derived: net income ÷ weighted average shares · filed 2021-03-18 | -$3.39 derived: net income ÷ weighted average shares · filed 2020-08-27 | ||
| 2018-12-31 | -$6.33 derived: net income ÷ weighted average shares · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |